volume 39, issue 45, P4030-4039 2018
DOI: 10.1093/eurheartj/ehy446
View full text
|
|
Share

Abstract: Metabolic syndrome is common in AF patients without overt CAD, and confers an independent, increased risk of MACE, including MI, coronary revascularization, and cardiac death. Given its prognostic implications, prevention and treatment of MetS may reduce the burden of non-thromboembolic complications in AF.